Patients suffering from nail-patella syndrome-induced pain report significant improvements in their health-related quality of life following CBD therapy, according to data published in the journal Nature: Scientific Reports. Nail-patella syndrome (NPS) is a rare genetic disease characterized by skeletal malformation and chronic pain.
Researchers assessed the safety and efficacy of CBD treatment in a cohort of 28 patients diagnosed with NPS. Study participants ingested pharmaceutical-grade synthetic CBD for three months.
Investigators reported: “Treatment (median dose of 900 mg/day) was associated with a significant reduction in pain intensity (mean score of 7.04 at initiation versus 4.04 at three months. … Health-related quality of life and other NPS-associated symptoms also improved in most patients. CBD treatment was well-tolerated and no elevations in liver enzyme levels were reported.”
The study’s authors concluded: “Oral treatment with synthetic CBD was associated with a significant reduction in pain in most of the patients with NPS included in our study and led to improvements in most of the NPS-associated symptoms analyzed. Hence, synthetic oral CBD appears to be a safe and effective treatment option for NPS-associated pain and may be an alternative to conventional analgesics for managing chronic pain in this pathology.”
